|
The prevalence of isolated hepatitis B core antibody and its related risk factors among male injected drug users in Isfahan prisons
Kiana Shirani1, Zary Nokhodian2, Nazila Kassaian3, Peyman Adibi4, Alireza Emami Naeini3, Behrooz Ataei3
1 Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Gastroenterology, Integrative Functional Gastroenterology Research Center,Isfahan University of Medical Sciences, Isfahan, Iran
| Date of Submission | 02-Mar-2013 |
| Date of Acceptance | 19-Feb-2014 |
| Date of Web Publication | 30-Jan-2015 |
Correspondence Address:
Behrooz Ataei
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2277-9175.148675
Background: The prevalence of isolated hepatitis B core antibody (anti-HBc) varies between 1% and 30% in different populations. Isolated anti-HBc-positive patients who suffer from occult hepatitis B virus (HBV) infection have the potential to transmit HBV infection. So isolated anti-HBc screening is a valuable tool to prevent HBV transmission. Considering the importance of isolated anti-HBc screening and high prevalence of HBV among injected drug users (IDU) prisoners, we designed this study to evaluate the isolated anti-HBc positivity among inmates with the history of IDU in our area.
Materials and Methods: We did this cross-sectional study from September 2009 to March 2010 among volunteer male IDU prisoners in Isfahan. Blood samples were taken from all of subjects and tested for HBV markers. Then a questionnaire containing socio-demographic, drug histories and high risk behaviors information was completed for all participants. Data analysis was done utilizing univariate analysis and multiple logistic regressions. A P < 0.05 was considered significant.
Results: Totally 970 male IDU prisoners (mean age 32.6 ± 8.1) were included in our study. The prevalence of isolated HBc Ab was 4.5%. Isolated anti-HBc significantly was related to tooth filling (OR: 2.62, CI: 1.20-7.14) and imprisonment (OR: 3.95, CI: 1.39-11.18 ) . We couldn't find any relationship between isolated anti-HBc positivity and addiction duration, incarceration frequency, recent incarceration duration or number of injection per month.
Conclusion: For screening high risk groups in parallel with hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb) and other viral markers, maybe it is better to check HBcAb too, because isolated HBcAb-positive patients may have occult hepatitis B infection which could transfer the infection to others. Keywords: Injected drug users, isolated anti hepatitis B core, prison
How to cite this article:
Shirani K, Nokhodian Z, Kassaian N, Adibi P, Naeini AE, Ataei B. The prevalence of isolated hepatitis B core antibody and its related risk factors among male injected drug users in Isfahan prisons. Adv Biomed Res 2015;4:17 |
How to cite this URL:
Shirani K, Nokhodian Z, Kassaian N, Adibi P, Naeini AE, Ataei B. The prevalence of isolated hepatitis B core antibody and its related risk factors among male injected drug users in Isfahan prisons. Adv Biomed Res [serial online] 2015 [cited 2023 Jun 1];4:17. Available from: https://www.advbiores.net/text.asp?2015/4/1/17/148675 |
| Introduction | |  |
It has been estimated that about two billion people all around the world are infected with hepatitis B virus (HBV). About 400 million of these people are affected with chronic HBV and develop liver failure, cirrhosis and hepatocellular carcinoma. [1],[2]
The risk of HBV infection is high among injected drug users (IDUs). [3],[4] The sharing of contaminated injection equipments and abnormal sex behaviors are known as the most important risk factors for HBV infection among IDUs. [5],[6],[7] Some studies have indicated that about one third of inmates are IDU. High prevalence of IDUs, drug injection and other high risk behaviors in prisons became suitable places for transmission of infection. [8],[9]
Hepatitis B surface antigen (HBsAg) and antibodies to the Hepatitis B core antibody (anti-HBc) are serological markers for HBV infection diagnosis. Anti-HBc develops in the period of HBV infection and persists for a long time. The simultaneous presence of anti-HBc with HBsAg shows current infection while its presence together with antibodies against HBsAg (anti-HBs) indicates that infection has been resolved. [10],[11] The prevalence of isolated positive anti-HBc, which is referred to anti-HBc positivity in the absence of both HBsAg and anti-HBs varies between 1% and 30% in different populations based on HBV endemicity in a particular area. [12],[13],[14] It has been reported that about 10-40% of patients with isolated anti-HBc are occult HBV patients. [15] These patients can transmit HBV infection and develop chronic liver diseases. [16],[17] Considering the high prevalence of HBV among IDU prisoners and the importance of isolated anti-HBc screening in order to prevent infection transmission by HBV latent carriers, we designed this study to evaluate the prevalence of anti-HBc positivity and its related risk factors in male IDUs in Isfahan prisons.
| Materials and methods | | |
This cross-sectional study was done among male IDUs in Isfahan prisons from September 2009 to March 2010. All prisoners with the history of drug injection based on their self-report and the confirmation of prison's health care professionals were included in our study. We informed subjects that the study is completely confidential and we obtained written informed consent from all of them. Blood samples (5 ml) were taken from each participant by trained prison's health personnel and sent to Infectious Disease Research Center Laboratory in cold boxes. To detect isolated anti-HBc-positive patients' sera from blood, specimens were tested using the fourth-generation enzyme-linked immunosorbent assay (ELISA) method to determine hepatitis B serum markers (HBs Ag, HBsAb, HBcAb). Then validated and reliable questionnaire [18] was completed for all of participants. Fortunately, 80% of male IDU prisoners participated in this study and all of them responded to the questioner. The questionnaire consisted of socio-demographic information, drug histories, sexual habits, incarceration information and other dangerous behaviors that are related to HBV transmission. Data analysis was performed using SPSS software, version 16, and univariate analysis (P < 0.05 was considered significant). Then significant variables in univariate analysis were entered in multiple logistic regression to determine the association between meaningful risk factors and isolated HBcAb positivity.
| Results | | |
We included 970 male IDU prisoners, aged 18 to 67 years (mean age 32.6 ± 8.1) in this study. Of these, 55.4% were married and 44.6% were single. 92%, 7% and 1% of participant with marriage history had been married once, twice and more, respectively. Subjects consisted of 956 Iranian, 11 Afghan, 2 Armenia and 1 Hindi. The distribution of educational status is mentioned in [Table 1]. The majority of our samples had junior high school (40%) and elementary school (37.3%) educations. About 18% of participants were in grades higher than junior high school and 4.5% of them were illiterate or had reading and writing ability.
The prevalence of isolated anti-HBc positivity was 4.5% (n = 44) in the current study. [Table 2] shows the frequency of related risk factors in studied subjects. There was a significant relationship between isolated HBc Ab positivity and the history of imprisonment and dental filling (P < 0.05) [Table 2] and [Table 3]. Isolated anti-HBc positivity was not related to the number of injection (median 30 times per month, range 1-500), addiction duration (median 12 years, range 0.5-57), frequency of incarceration (median 3 times, range 1-37) and duration of recent incarceration (median 3.66 years, range 0.08-35). There were also no relationship between socio-demographic characteristics and isolated anti-HBc positivity. | Table 3: Multiple logistic regressions of risk factors for anti-HBc positivity
Click here to view |
| Discussion | | |
In the current study, we estimated the prevalence of isolated anti-HBc positive male IDU prisoners in Isfahan province. The prevalence of isolated anti-HBc was about 4.5% among our subjects. As we searched, we only could find one study that had determined the prevalence of isolated anti-HBc among IDUs. They included 153 IDUs of Arak, central province of Iran; in their study, they found that about 7.84% of subjects have isolated anti-HBc. [19]
In this study, there was a significant relationship between the presence of isolated anti-HBc and a history of former imprisonment(s) except this time. Based on our knowledge, this study is the only one which has examined the relationship between high risk behaviors and isolated anti-HBc presence. The significant relationship between former imprisonment and HBV infection has been mentioned in some studies but its reasons are not clear. [20],[21] It seems that sharing contaminated injection drug equipments is higher in prisons. In a study performed by Liang et al. they found an association between HBcAb positivity and HIV and they found that HBcAb positivity is higher in patients with HIV and HCV coinfection. [22] In this study, we didn't assess HIV and HCV on study group, and these two infections can be confounding factors that are common in IDUs especially IDU prisoners, which can influence on our results. On the other hand, participants with history of former imprisonment maybe infected with HIV or HCV or both more likely than people without history of former imprisonment, and in fact coinfection with HIV, HCV or both could be the principle cause for isolated HBc Ab positivity in participant with history of former imprisonment. [22] So doing further studies is necessary to clarify the relationship between imprisonment and isolated anti-HBc positivity.
We also found that tooth filling is related to isolated anti-HBc positivity. This fact that dental procedures are associated with HBV infection transmission and high frequency of dental problems in IDUs can explain the relation between isolated anti-HBc and tooth filling. [23],[24] In a study by Keyvani et al. on hemodialysis patients they found a relationship between isolated HBc Ab positivity and diabetes mellitus, older age and older age when dialysis started, [25] but in this study there were no relationship between isolated HBc Ab positivity and demographic characteristics such as age.
Isolated anti-HBc may reflect resolved previous HBV infection with undetectable level of HBsAb, window phase of an acute infection and chronic HBV infection with undetectable HBs Ag levels that is called occult HBV. [26],[27],[28] Ramezani and her colleagues in a study detected occult HBV patients by doing HBV-DNA detection tests on subjects with isolated anti-HBc marker and concluded that isolated anti-HBc screening among high risk groups can reflect occult HBV. [29]
For screening of HBV infection among high risk groups, in parallel with HBsAg, HBsAb and other viral markers, maybe it is better to check HBcAb too, because isolated HBcAb positive patients may have occult hepatitis B infection which could transfer the infection to others. So it seems that doing other studies in future in order to detect occult HBV patients among cases with isolated anti-HBc is necessary to determine if isolated anti-HBc screening is a useful tool to prevent HBV infection transmission among IDU prisoners in our area.
| Acknowledgment | | |
The authors thank Research Council of Isfahan University of Medical Sciences for providing financial support for this study and Isfahan prisons' staffs for their active (worthy) assistance in doing this project.
| References | | |
| 1. | Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 2006;28:112-25.  |
| 2. | Ali M, Idrees M, Ali L, Hussain A, Ur Rehman I, Saleem S, et al. Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes. Virol J 2011;8:102. |
| 3. | Bialek SR, Bower WA, Mottram K, Purchase D, Nakano T, Nainan O, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 2005;82:468-78. |
| 4. | Tseng FC, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46:666-71. |
| 5. | Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000; 18:145-50. |
| 6. | Garfein, RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61. |
| 7. | Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003;157:467-71. |
| 8. | Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004; 94:1218-23. |
| 9. | Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Quaye IK, Hesse IF, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol 2006;55:593-7. |
| 10. | Shim J, Kim KY, Kim BH, Chun H, Lee MS, Hwangbo Y, et al. Anti-hepatitis B core antibody is not required for prevaccination screening in healthcare workers. Vaccine 2011;29:1721-6. |
| 11. | Silva CM, Costi C, Costa C, Michelon C, Oravec R, Ramos AB, et al. Low rate of occult hepatitis B virus infection among anti-HBc positive blood donors living in a low prevalence region in Brazil. J Infect 2005; 51:24-9. |
| 12. | Sofian M, Aghakhani A, Izadi N, Banifazl M, Kalantar E, Eslamifar A, et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010;14:308-10. |
| 13. | Alhababi F, Sallam TA, Tong CY. The significance of 'anti-HBc only' in the clinical virology laboratory. J Clin Virol 2003;27:162-9. |
| 14. | Pondé RA, Cardoso DD, Ferro MO. The underlying mechanisms for the 'anti-HBc alone' serological profile. Arch Virol 2010;155:149-58. |
| 15. | Haushofer AC, Hauer R, Brunner H, Köller U, Trubert-Exinger D, Halbmayer WM, et al. No evidence of hepatitis B virus activity in patients with anti-HBc antibody positivity with or without anti-hepatitis C virus antibody positivity. J Clin Virol 2004;29:221-3. |
| 16. | Khamesipour A, Amiri ZM, Kafiabad SA, Saadat F, Mansour-ghanaei F, Esteghamati AR, et al. Frequency of hepatitis B virus DNA in anti-HBc positive, HbsAg negative blood donors in Rasht, northern Iran. Transfus Apher Sci 2011;45:195-7. |
| 17. | Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009;13:488-92. |
| 18. | Kassaian N, Adibi P, Kafashaian A, Yaran M, Nokhodian Z, Shoaei P, et al. Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran. Int J Prev Med 2012;3 Suppl 1:S156-61. |
| 19. | Sofian M, Mahdaviani FS, Izadi N, Mousavinejad A, Sarmadian H, Zarinfar N, et al. Comparison the prevalence of isolated Hepatitis B core antibody among injection drug users with blood donors in central province in Iran. Iranian South Med J 2011;3:173-8. |
| 20. | Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners-NSW, 1996. Aust N Z J Public Health 1999;23:377-84. |
| 21. | Weinbaum C, Lyerla R, Margolis HS; Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-36; quiz CE1-4. |
| 22. | Liang SH, Chen TJ, Lee SS, Tseng FC, Huang CK, Lai CH, et al. Risk factors of isolated antibody against core antigen of hepatitis B virus: Association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr 2010;54:122-8. |
| 23. | Qureshi H, Arif A, Riaz K, Alam SE, Ahmed W, Mujeeb SA. Determination of risk factors for hepatitis B and C in male patients suffering from chronic hepatitis. BMC Res Notes 2009;2:212. |
| 24. | Laslett AM, Dietze P, Dwyer R. The oral health of street-recruited injecting drug users: Prevalence and correlates of problems. Addiction 2008; 103:1821-5. |
| 25. | Keyvani H, Agah S, Kabir A, Alavian SM. Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodialysis patients: A nationwide study. Ann Hepatol 2013;12:213-9. |
| 26. | Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern "anti-HBC alone": Report on a workshop. J Med Virol 2000;62:450-5. |
| 27. | Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001; 64:312-9. |
| 28. | Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. |
| 29. | Ramezani A, Banifazl A, Eslamifar A, Aghakhani A. Serological pattern of anti-HBc alone infers occult hepatitis B virus infection in high-risk individuals in Iran. J Infect Dev Ctries 2010;4:658-61. |
[Table 1], [Table 2], [Table 3]
| This article has been cited by | | 1 |
Prevalence of overt and occult hepatitis B virus infection among an incarcerated population of Central-Western Brazil |
|
| Juliana Menara de Souza Marques, Marcos André Matos, Ágabo Macedo Costa Silva, Nara Rúbia Freitas, Michele Tiemi Okita, Sara de Oliveira Souza, Megmar Aparecida dos Santos Carneiro, Regina Maria Bringel Martins, Márcia Alves Dias Matos | | Acta Tropica. 2023; 241: 106886 | | [Pubmed] | [DOI] | | | 2 |
Seroprevalence and factors associated with hepatitis B virus exposure in the incarcerated population from southern Brazil |
|
| Joelma Goetz de Gois, Sthefanny Josephine Klein Ottoni Guedes, Ana Paula Vieira, Franciele Aní Caovilla Follador, Luís Fernando Dip, Léia Carolina Lucio, Kérley Braga Pereira Bento Casaril, Paulo Cezar Nunes Fortes, Valdir Spada Júnior, Guilherme Welter Wendt, Lirane Elize Defante Ferreto, Jason T. Blackard | | PLOS ONE. 2022; 17(11): e0278029 | | [Pubmed] | [DOI] | | | 3 |
Blood Lead Exposure and Association With Hepatitis B Core Antibody in the United States: NHANES 2011–2018 |
|
| Kexing Han, Tengyao He, Siran Huang, Weijie Sun, Yufeng Gao | | Frontiers in Public Health. 2022; 10 | | [Pubmed] | [DOI] | | | 4 |
Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study |
|
| Cristina Stasi,Mirko Monnini,Valerio Cellesi,Marco Salvadori,Daniele Marri,Mateo Ameglio,Andrea Gabbuti,Teresa Di Fiandra,Fabio Voller,Caterina Silvestri | | Vaccine. 2019; 37(11): 1412 | | [Pubmed] | [DOI] | | | 5 |
Responses to hepatitis B vaccine in isolated anti-HBc positive adults |
|
| Jun Yao,Wen Ren,Yongdi Chen,Zhenggang Jiang,Lingzhi Shen,Huan Shan,Xuewei Dai,Jing Li,Ying Liu,Yan Qiu,Jingjing Ren | | Human Vaccines & Immunotherapeutics. 2016; : 1 | | [Pubmed] | [DOI] | | | 6 |
The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey |
|
| Derya Keten,Mehmet Emin Ova,Hamit Sirri Keten,Alper Keten,Evrim Gulderen,Seray Tumer,Ahmet Caliskan,Suleyman Kulotu | | Jundishapur Journal of Microbiology. 2016; 9(2) | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for